CDT Equity Inc. (CDT) CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CDT Equity Inc. NASDAQ:CDT Healthcare · Biotechnology
Mkt Cap $684K
EV -
SI 0.3%
Net Cash/Sh -
AH After hours +5.56%$0.3800 Prev close $0.3770 -4.51%Close $0.3600 +5.56%Now $0.3800 VOL 317K $ Vol $115K RVOL 0.13x
Mkt Cap $684K
EV -
VOL 317K sh
$ Vol $115K
RVOL 0.13×
SI 0.3%
Net Cash/Sh -
Press Release
CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
CDT Equity has commenced human skin studies with QIMA Life Sciences evaluating its proprietary tapinarof combinations in vitiligo, formally kicking off the partnership announced September 18, 2026. The studies use human skin from healthy donors and patients to generate preclinical data in the most physiologically relevant setting available, which CDT says will underpin the licensing data package for out-licensing the combinations.
• 6d ago AI analysis › Press Release
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
CDT Equity welcomed a new HHS interim enforcement discretion policy covering six peptide bulk drug substances, including BPC-157 and TB-500, while FDA rulemaking on the Section 503A Bulks List continues. Under the policy, HHS does not intend to take enforcement action against qualifying pharmacies, federal facilities, or licensed physicians compounding the specified peptides, subject to Section 503A conditions. CDT believes the development supports its strategic investment in U.S.
• 18d ago AI analysis › Press Release
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
CDT Equity entered an evaluation agreement with Manoira Corporation to assess whether CDT's clinical-stage assets AZD1656 and AZD5904 can enhance Manoira's upcoming animal health products. Manoira plans to launch its first animal health range in Q1 2027 using licensed cannabinoid cocrystal and solid-form technologies, and is currently in manufacturing and testing.
• 21d ago AI analysis › Press Release
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
CDT Equity highlighted a new solid-form patent filing by Sarborg Limited covering a first-in-class respiratory medicine addressing a treatment market estimated at more than $20 billion annually. CDT holds 1,290 Sarborg shares, or 22.7% of its issued capital, valued at roughly $161 million based on Sarborg's latest raise at $125,000 per share.
• 1mo ago AI analysis › Press Release
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
CDT Equity Inc. (Nasdaq: CDT) highlighted a new IP filing by Sarborg Limited applying quantum sampling to disease biology and drug discovery, covering 150 disease networks including Crohn's disease, COPD, and psoriasis. CDT holds 1,290 shares in Sarborg, a 22.7% stake; Sarborg's latest raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
• 1mo ago AI analysis › Press Release ● Major
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity's board approved a 1-for-25 reverse stock split to ensure continued compliance with the Nasdaq bid-price rule. The split becomes effective September 28, 2026 at 5:00 pm ET, with split-adjusted trading under ticker CDT beginning September 29. Outstanding shares will fall to approximately 1,013,515, with fractional shares cashed out and equity awards, warrants, and convertibles proportionally adjusted.
• 1mo ago AI analysis › Press Release
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT Equity Inc. entered a partnership with QIMA Life Sciences, a preclinical dermatology CRO, to evaluate several CDT assets in autoimmune skin diseases using human skin from both healthy donors and patients. Initial studies center on tapinarof (VTAMA), already approved for plaque psoriasis and atopic dermatitis in the US and Japan; CDT holds solid-form and method-of-use patents around tapinarof combinations and is targeting a second-generation product with greater efficacy and broader patient reach.
• 1mo ago AI analysis › Press Release
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
CDT Equity highlighted portfolio company Sarborg Limited's successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery, covering disease signatures for depression, bipolar disorder, anxiety and schizophrenia. CDT holds 1,290 Sarborg shares, representing 22.7% of the issued share capital; Sarborg's latest capital raise priced at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
• 2mo ago AI analysis › Press Release
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity confirmed that it no longer has any outstanding deficiencies with The Nasdaq Stock Market, removing the risk of delisting. As of August 31, 2026, the company reported 13,693,866 shares outstanding and a market capitalization of approximately $23.0 million.
• 2mo ago AI analysis › Press Release
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
CDT Equity Inc. appointed co-founder James Bligh as Chief Executive Officer to lead the company's next phase of growth, leveraging his background in public markets and corporate finance. Simultaneously, Dr. Andrew Regan was named CEO of Sarborg Limited, a quantum signature intelligence business in which CDT holds a 22% strategic stake.
• 2mo ago AI analysis › Press Release
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
CDT Equity validated new solid forms and crystal structures for its existing drug compounds, demonstrating enhanced stability and solubility compared to prior forms. Using Sarborg's Signature Intelligence AI, the company identified new therapeutic uses for these assets and filed patents to protect the findings, targeting underserved patient groups.
• 2mo ago AI analysis › Press Release
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
CDT Equity Inc. entered into a SAFE note investment with Pep'd Inc., a US-based peptide company, marking its entry into the US peptide therapeutics market with a valuation cap of $10 million. The global peptide market is projected to grow at an 8.7% CAGR to reach $294.6 billion by 2033, and CDT plans to leverage AI-enabled approaches with Pep'd to identify new opportunities in this sector. Investors should note that Pep'd is controlled by Dr.
• 2mo ago AI analysis › Press Release
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
CDT Equity announced it will increase its equity stake in Sarborg Limited to 22.7% through the issuance of pre-funded warrants for up to 12.1 million shares, pending shareholder approval at the annual meeting on August 28. Sarborg, an agentic AI business, has expanded its Signature Intelligence platform into quantum computing via SarborgQ and broadened its IP portfolio into agriculture, supporting an implied valuation of approximately $638.3 million. CEO Dr.
• 3mo ago AI analysis › Press Release
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
CDT Equity highlighted a patent filing by its portfolio company Sarborg Limited covering sugarcane cultivation interventions developed using the quantum-enabled PRISM platform. The filing encompasses 606 field-applicable combinations identified by SarborgQ's quantum computing engine, marking an expansion of the platform into the agricultural sector.
• 3mo ago AI analysis › Press Release ● Major
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Inc. announced a 1-for-10 reverse stock split, approved by its board of directors to ensure continued compliance with Nasdaq's minimum bid price rule. The reverse split is effective as of July 17, 2026, with trading on a split-adjusted basis expected to commence on July 20 under the existing CDT ticker.
• 4mo ago AI analysis › Press Release
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
CDT Equity highlighted that its subsidiary Sarborg is expanding its Signature Intelligence platform to include quantum-assisted coformer selection via its SarborgQ division. The technology utilizes a proprietary database of more than 850 coformers and agentic AI to accelerate solid-form development and improve decision-making.
• 4mo ago AI analysis › Press Release
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
CDT Equity noted that its portfolio company Sarborg secured funding at a price of $125,000 per share, implying a fully diluted valuation of approximately $638.3 million. Based on this transaction, CDT's 1,020-share stake in Sarborg is valued at roughly $127.5 million, marking a significant increase in the carrying value of this strategic asset.
• 4mo ago AI analysis › Press Release
CDT Equity Announces Debt Update and New Loan Facility
CDT Equity has restructured its debt by paying off all outstanding amounts to Alliance Global Partners and Ascent Partners, eliminating over $6.3 million in legacy obligations. To support working capital, the company entered into a new loan agreement with JJ Astor for up to $1.46 million, with an initial tranche of $268k funded. CEO Dr.
• 5mo ago AI analysis › Press Release
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
CDT Equity Inc. received a Nasdaq deficiency letter on May 21, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The notice cites a violation of Nasdaq Listing Rule 5250(c)(1) regarding periodic filing requirements but does not immediately affect the listing or trading of CDT securities.
• 5mo ago AI analysis › Press Release
CDT Announces Canadian Patent for AZD5904 in Male Infertility
CDT Equity announced that the patent covering AZD5904 for male infertility has been granted in Canada, completing approval in all key pharmaceutical target markets. The company states this extensive geographical coverage strengthens its IP position as it continues discussions regarding potential licensing and strategic partnering opportunities.
• 5mo ago AI analysis › Press Release
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
CDT Equity noted that Sarborg Limited, in which it holds a 20% stake, filed a Substance of Matter patent covering two compounds for the cystic fibrosis market. Sarborg utilized its proprietary AI platform to achieve the patent filing in less than three weeks, a timeline CDT views as strong validation of the platform's capabilities.
• 6mo ago AI analysis › Press Release
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
CDT Equity announced that its lead asset AZD5904, licensed from AstraZeneca, has advanced into the Patent Cooperation Treaty phase to secure global intellectual property protection. The drug demonstrated a favorable safety profile with 181 subjects dosed across five Phase 1 studies, targeting idiopathic male infertility and oncology-associated infertility.
• 6mo ago AI analysis › Press Release
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
globenewswire.com • 7mo ago Press Release
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
globenewswire.com • 7mo ago Press Release ● Major
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
globenewswire.com • 7mo ago Press Release ● Critical
CDT Equity Inc. Announces Reverse Stock Split
globenewswire.com • 7mo ago Press Release
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
globenewswire.com • 7mo ago Press Release
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
globenewswire.com • 8mo ago